Google
OKUR — ONKURE THERAPEUTICS, INC. (Healthcare >> Biotechnology)
OKUR FAQ
What is OKUR's ROE?
ONKURE THERAPEUTICS, INC. reports a Return on Equity (ROE) of -31.87%.
What is OKUR's dividend yield?
ONKURE THERAPEUTICS, INC. offers a dividend yield of 0.00%.
What is OKUR's Deepscope Quality Score?
Deepscope rates OKUR's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OKUR?
Deepscope's AI Timing Score for OKUR is 89 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OKUR belong to?
ONKURE THERAPEUTICS, INC. is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 4.19
Price
-0.11
(-2.56%)
Day Change
|
|
|---|
OKUR, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Growth of ROA was below our criteria in the last year.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 90 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 4.19 |
| PBV / Sector |
0.92 / 4.63
GREAT
|
| Earning Per Share | -1.45 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
1.19 M
GREAT
|
| Average 1W Daily Value |
2.62 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:05 |
| Symbol | OKUR |
| Name | ONKURE THERAPEUTICS, INC. |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 40.40 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 169.66 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 6707 Winchester Circle, Boulder, CO, United States, 80301
Phone: 720-307-2892
Website: https://onkuretherapeutics.com
Sector: Healthcare >> Biotechnology
Description: OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
